The DOI matches its Crossref record; 249 of the 249 references it cites were found in a registry or an index.
Cancer immune evasion, immunoediting and intratumour heterogeneity
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Identification of human brain tumour initiating cells
Singh, S. K., Hawkins, C., Clarke, I. D., Squire, J. A., Bayani, J., Hide, T., Henkelman, R. M., Cusimano, M. D., & Dirks, P. B. (2004) · Nature · doi:10.1038/nature03128 · Cited by 7,433
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231 · cited 1×
“Stromal barriers as a mechanism of immune exclusion have been described, for example, in pancreatic cancer 112,113 and are associated with poor patient outcomes and responsiveness to ICB therapy 114,115 .”
Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
Patel, A. P., Tirosh, I., Trombetta, J. J., Shalek, A. K., Gillespie, S. M., Wakimoto, H., Cahill, D. P., Nahed, B. V., Curry, W. T., Martuza, R. L., et al. (2014) · Science · doi:10.1126/science.1254257 · Cited by 5,063 · cited 1×
“In line with this notion, ITH is associated with poor patient outcomes 176,177,239 , as well as poor responsiveness to immune checkpoint blockade (ICB) therapy 25 , chimeric antigen receptor (CAR)-”
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812 · cited 1×
“Its role in modulating T cell function has recently gained attention as data show an association between microbiome quality and responsiveness to ICB 168,169 and chimeric antigen receptor (CAR)-”
Molecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397 · cited 1×
“T cell chemoattraction is associated with T cell infiltration into the tumour in melanoma, ovarian and colorectal cancers 93–95 and was shown to be necessary for responsiveness to ICB therapy 96 .”
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237 · cited 2×
“…mechanism impairing cancer cell recognition by CD8 + T cells is suppression of HLA class I expression, which has been observed in melanoma, lung, colorectal and other cancers and is associated with poor patient outcomes and responsiveness to T cell-based immunotherapies including ICB 37,67–71 .”
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
Qian, B.-Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L. R., Kaiser, E. A., Snyder, L. A., & Pollard, J. W. (2011) · Nature · doi:10.1038/nature10138 · Cited by 2,874 · cited 1×
“Moreover, they can support regional immune evasion (discussed subsequently) through the production of soluble factors including vascular endothelial growth factor (VEGF) and transforming growth factor-β (TGFβ) 62–64 .”
Clonal heterogeneity and tumor evolution: past, present, and the future
McGranahan, N., & Swanton, C. (2017) · Cell · doi:10.1016/j.cell.2017.01.018 · Cited by 2,840
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830 · cited 7×
“…immune evasion mechanisms and tissue-specific mechanisms of tolerance are associated with a lack of T cell infiltration (‘immune cold’ tumours) 30,38,39 , regional mechanisms restrict T cells to the tumour margins and local mechanisms do not interfere with T cell infiltration (‘immune hot’…”
InfluentialSelf-citationNivolumab plus ipilimumab in advanced non-small-cell lung cancer
Hellmann, M. D., Paz-Ares, L., Bernabe Caro, R., Zurawski, B., Kim, S.-W., Carcereny Costa, E., Park, K., Alexandru, A., Lupinacci, L., de la Mora Jimenez, E., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910231 · Cited by 2,823
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412690 · Cited by 2,701
T cell exclusion, immune privilege, and the tumor microenvironment
Joyce, J. A., & Fearon, D. T. (2015) · Science · doi:10.1126/science.aaa6204 · Cited by 2,473
Reynisson, B., Alvarez, B., Paul, S., Peters, B., & Nielsen, M. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa379 · Cited by 2,361
Tracking the Evolution of Non–Small-Cell Lung Cancer
Jamal-Hanjani, M., Wilson, G. A., McGranahan, N., Birkbak, N. J., Watkins, T. B. K., Veeriah, S., Shafi, S., Johnson, D. H., Mitter, R., Rosenthal, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616288 · Cited by 2,349
A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell
Ridge, J. P., Di Rosa, F., & Matzinger, P. (1998) · Nature · doi:10.1038/30989 · Cited by 2,342
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
Cristescu, R., Mogg, R., Ayers, M., Albright, A., Murphy, E., Yearley, J., Sher, X., Liu, X. Q., Lu, H., Nebozhyn, M., et al. (2018) · Science · doi:10.1126/science.aar3593 · Cited by 2,301
The Immune Epitope Database (IEDB): 2018 update
Vita, R., Mahajan, S., Overton, J. A., Dhanda, S. K., Martini, S., Cantrell, J. R., Wheeler, D. K., Sette, A., & Peters, B. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1006 · Cited by 2,186
A Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
Shah, S. P., Roth, A., Goya, R., Oloumi, A., Ha, G., Zhao, Y., Turashvili, G., Ding, J., Tse, K., Haffari, G., et al. (2012) · Nature · doi:10.1038/nature10933 · Cited by 1,967 · cited 1×
“Further in line with this observation, branching evolution 139,177,208 and neutral evolution 209 , which induce ITH, are the most prevalent modes of tumour evolution 19,20 .”
Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer
Costa, A., Kieffer, Y., Scholer-Dahirel, A., Pelon, F., Bourachot, B., Cardon, M., Sirven, P., Magagna, I., Fuhrmann, L., Bernard, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.011 · Cited by 1,705 · cited 2×
“Cancer-associated fibroblasts are induced by TGFβ, which can be produced by cancer cells through various mechanisms 103,120 .”
IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis
Coffelt, S. B., Kersten, K., Doornebal, C. W., Weiden, J., Vrijland, K., Hau, C.-S., Verstegen, N. J. M., Ciampricotti, M., Hawinkels, L. J. A. C., Jonkers, J., et al. (2015) · Nature · doi:10.1038/nature14282 · Cited by 1,703 · cited 1×
“Another example is the tissue-resident macrophages in the lungs that contribute to suppression of T cells 151 and recruitment of inhibitory immune cell populations to lung tumours 152–154 .”
The Concept of Immunological Surveillance
Burnet, F. M. (2015) · Progress in Tumor Research · doi:10.1159/000386035 · Cited by 1,656
Blank, C. U., Haining, W. N., Held, W., Hogan, P. G., Kallies, A., Lugli, E., Lynn, R. C., Philip, M., Rao, A., Restifo, N. P., et al. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0221-9 · Cited by 1,603
Saxena, M., van der Burg, S. H., Melief, C. J. M., & Bhardwaj, N. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00346-0 · Cited by 1,581
Spectrum of cancer risk among US solid organ transplant recipients
Engels, E. A., Pfeiffer, R. M., Fraumeni, J. F., Kasiske, B. L., Israni, A. K., Snyder, J. J., Wolfe, R. A., Goodrich, N. P., Bayakly, A. R., Clarke, C. A., et al. (2011) · JAMA · doi:10.1001/jama.2011.1592 · Cited by 1,524 · cited 1×
“Moreover, although many of the early studies arguing against the process of immunoediting 216,217 have since been refuted 218,219 , some more recent reports also question effective immunoediting in human cancers 220,221 .”
Universal Patterns of Selection in Cancer and Somatic Tissues
Martincorena, I., Raine, K. M., Gerstung, M., Dawson, K. J., Haase, K., Van Loo, P., Davies, H., Stratton, M. R., & Campbell, P. J. (2017) · Cell · doi:10.1016/j.cell.2017.09.042 · Cited by 1,523
Spranger, S., Dai, D., Horton, B., & Gajewski, T. F. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.003 · Cited by 1,441 · cited 3×
“In addition to the priming of naive T cells, cDC1s express CXCL9 and CXCL10 to recruit activated T cells to the TME 89,90,92 and form supportive niches within the TME to maintain effector T cell function 129–131 .”
Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer
Rojas, L. A., Sethna, Z., Soares, K. C., Olcese, C., Pang, N., Patterson, E., Lihm, J., Ceglia, N., Guasp, P., Chu, A., et al. (2023) · Nature · doi:10.1038/s41586-023-06063-y · Cited by 1,432
Hiam-Galvez, K. J., Allen, B. M., & Spitzer, M. H. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00347-z · Cited by 1,400
The microbiome and human cancer
Sepich-Poore, G. D., Zitvogel, L., Straussman, R., Hasty, J., Wargo, J. A., & Knight, R. (2021) · Science · doi:10.1126/science.abc4552 · Cited by 1,332
Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution
McGranahan, N., Rosenthal, R., Hiley, C. T., Rowan, A. J., Watkins, T. B. K., Wilson, G. A., Birkbak, N. J., Veeriah, S., Van Loo, P., Herrero, J., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.001 · Cited by 1,298
The Cytosolic DNA-Sensing cGAS–STING Pathway in Cancer
Kwon, J., & Bakhoum, S. F. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0761 · Cited by 1,293
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
Matsushita, H., Vesely, M. D., Koboldt, D. C., Rickert, C. G., Uppaluri, R., Magrini, V. J., Arthur, C. D., White, J. M., Chen, Y.-S., Shea, L. K., et al. (2012) · Nature · doi:10.1038/nature10755 · Cited by 1,288
Clinical and therapeutic relevance of cancer-associated fibroblasts
Chen, Y., McAndrews, K. M., & Kalluri, R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00546-5 · Cited by 1,230 · cited 1×
“116,117).”
Melief, C. J. M., van Hall, T., Arens, R., Ossendorp, F., & van der Burg, S. H. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80009 · Cited by 1,164
Salmon, H., Franciszkiewicz, K., Damotte, D., Dieu-Nosjean, M.-C., Validire, P., Trautmann, A., Mami-Chouaib, F., & Donnadieu, E. (2012) · Journal of Clinical Investigation · doi:10.1172/jci45817 · Cited by 1,138
Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment
Harlin, H., Meng, Y., Peterson, A. C., Zha, Y., Tretiakova, M., Slingluff, C., McKee, M., & Gajewski, T. F. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2281 · Cited by 1,121
Human neoplasms elicit multiple specific immune responses in the autologous host.
Sahin, U., Türeci, O., Schmitt, H., Cochlovius, B., Johannes, T., Schmits, R., Stenner, F., Luo, G., Schobert, I., & Pfreundschuh, M. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.25.11810 · Cited by 1,078
Robbins, P. F., Lu, Y.-C., El-Gamil, M., Li, Y. F., Gross, C., Gartner, J., Lin, J. C., Teer, J. K., Cliften, P., Tycksen, E., et al. (2013) · Nature Medicine · doi:10.1038/nm.3161 · Cited by 1,072
Cancer after Kidney Transplantation in the United States
Kasiske, B. L., Snyder, J. J., Gilbertson, D. T., & Wang, C. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2004.00450.x · Cited by 1,071
Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
Motz, G. T., Santoro, S. P., Wang, L.-P., Garrabrant, T., Lastra, R. R., Hagemann, I. S., Lal, P., Feldman, M. D., Benencia, F., & Coukos, G. (2014) · Nature Medicine · doi:10.1038/nm.3541 · Cited by 1,035
Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance
Marusyk, A., Janiszewska, M., & Polyak, K. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.007 · Cited by 1,009
PyClone: statistical inference of clonal population structure in cancer
Roth, A., Khattra, J., Yap, D., Wan, A., Laks, E., Biele, J., Ha, G., Aparicio, S., Bouchard-Côté, A., & Shah, S. P. (2014) · Nature Methods · doi:10.1038/nmeth.2883 · Cited by 999
The MYC oncogene — the grand orchestrator of cancer growth and immune evasion
Dhanasekaran, R., Deutzmann, A., Mahauad-Fernandez, W. D., Hansen, A. S., Gouw, A. M., & Felsher, D. W. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00549-2 · Cited by 986
Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing
Zhang, J., Fujimoto, J., Zhang, J., Wedge, D. C., Song, X., Zhang, J., Seth, S., Chow, C.-W., Cao, Y., Gumbs, C., et al. (2014) · Science · doi:10.1126/science.1256930 · Cited by 965
The cancer-immunity cycle: Indication, genotype, and immunotype
Mellman, I., Chen, D. S., Powles, T., & Turley, S. J. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.011 · Cited by 953
Bayne, L. J., Beatty, G. L., Jhala, N., Clark, C. E., Rhim, A. D., Stanger, B. Z., & Vonderheide, R. H. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.025 · Cited by 947
Neoantigen-directed immune escape in lung cancer evolution
The TRACERx consortium, Rosenthal, R., Cadieux, E. L., Salgado, R., Bakir, M. A., Moore, D. A., Hiley, C. T., Lund, T., Tanić, M., Reading, J. L., et al. (2019) · Nature · doi:10.1038/s41586-019-1032-7 · Cited by 946
Liver tumour immune microenvironment subtypes and neutrophil heterogeneity
Xue, R., Zhang, Q., Cao, Q., Kong, R., Xiang, X., Liu, H., Feng, M., Wang, F., Cheng, J., Li, Z., et al. (2022) · Nature · doi:10.1038/s41586-022-05400-x · Cited by 935
Ruiz de Galarreta, M., Bresnahan, E., Molina-Sánchez, P., Lindblad, K. E., Maier, B., Sia, D., Puigvehi, M., Miguela, V., Casanova-Acebes, M., Dhainaut, M., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0074 · Cited by 912 · cited 2×
“30,124).”
Quezada, S. A., Simpson, T. R., Peggs, K. S., Merghoub, T., Vider, J., Fan, X., Blasberg, R., Yagita, H., Muranski, P., Antony, P. A., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091918 · Cited by 898
Strand, S., Hofmann, W. J., Hug, H., Müller, M., Otto, G., Strand, D., Mariani, S. M., Stremmel, W., Krammer, P. H., & Galle, P. R. (1996) · Nature Medicine · doi:10.1038/nm1296-1361 · Cited by 897
Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition
Litchfield, K., Reading, J. L., Puttick, C., Thakkar, K., Abbosh, C., Bentham, R., Watkins, T. B. K., Rosenthal, R., Biswas, D., Rowan, A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.002 · Cited by 893 · cited 9×
“The immune phenotype of a tumour, for instance, can be used as a surrogate for the categories of immune evasion mechanisms 210,211 and is a key predictor of response to ICB therapy across different cancer entities 25,212 .”
InfluentialIncrease of regulatory T cells in the peripheral blood of cancer patients.
Wolf, A. M., Wolf, D. G. F., Steurer, M., Gastl, G. A., Gunsilius, E., & Grubeck-Loebenstein, B. (2003) · PubMed · Cited by 891
Spatially organized multicellular immune hubs in human colorectal cancer
Pelka, K., Hofree, M., Chen, J. H., Sarkizova, S., Pirl, J. D., Jorgji, V., Bejnood, A., Dionne, D., Ge, W. H., Xu, K. H., et al. (2021) · Cell · doi:10.1016/j.cell.2021.08.003 · Cited by 874
Dominance and Crypticity of T Cell Antigenic Determinants
Sercarz, E. (1993) · Annual Review of Immunology · doi:10.1146/annurev.immunol.11.1.729 · Cited by 855
The complex role of tumor-infiltrating macrophages
Christofides, A., Strauss, L., Yeo, A., Cao, C., Charest, A., & Boussiotis, V. A. (2022) · Nature Immunology · doi:10.1038/s41590-022-01267-2 · Cited by 849
MHC-II neoantigens shape tumour immunity and response to immunotherapy
Alspach, E., Lussier, D. M., Miceli, A. P., Kizhvatov, I., DuPage, M., Luoma, A. M., Meng, W., Lichti, C. F., Esaulova, E., Vomund, A. N., et al. (2019) · Nature · doi:10.1038/s41586-019-1671-8 · Cited by 846 · cited 2×
“Indeed, CD4 + T cell responses are critical for ICB therapy responses even against HLA class II-negative tumours by providing help to CD8 + T cells (and B cells 82 ), as shown in a mouse sarcoma model 78 .”
Human tumor antigens recognized by T lymphocytes.
Boon, T., & van der Bruggen, P. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.3.725 · Cited by 842
An intra-tumoral niche maintains and differentiates stem-like CD8 T cells
Jansen, C. S., Prokhnevska, N., Master, V. A., Sanda, M. G., Carlisle, J. W., Bilen, M. A., Cardenas, M., Wilkinson, S., Lake, R., Sowalsky, A. G., et al. (2019) · Nature · doi:10.1038/s41586-019-1836-5 · Cited by 817
van Rooij, N., van Buuren, M. M., Philips, D., Velds, A., Toebes, M., Heemskerk, B., van Dijk, L. J. A., Behjati, S., Hilkmann, H., el Atmioui, D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.7521 · Cited by 798 · cited 1×
“Antigen-specific immunoediting may also occur in the context of immune checkpoint blockade therapy 227 .”
Wu, F., Fan, J., He, Y., Xiong, A., Yu, J., Li, Y., Zhang, Y., Zhao, W., Zhou, F., Li, W., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22801-0 · Cited by 796
Cancer classification using the Immunoscore: a worldwide task force
Galon, J., Pagès, F., Marincola, F. M., Angell, H. K., Thurin, M., Lugli, A., Zlobec, I., Berger, A., Bifulco, C., Botti, G., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-205 · Cited by 791
PD-L1 expression in human cancers and its association with clinical outcomes
Yu, J., Wang, X., Teng, F., & Kong, L. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s105862 · Cited by 787
Gettinger, S., Choi, J., Hastings, K., Truini, A., Datar, I., Sowell, R., Wurtz, A., Dong, W., Cai, G., Melnick, M. A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0593 · Cited by 787
Neutrophils in cancer: heterogeneous and multifaceted
Hedrick, C. C., & Malanchi, I. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00571-6 · Cited by 768
Lenz, H.-J., Van Cutsem, E., Luisa Limon, M., Wong, K. Y. M., Hendlisz, A., Aglietta, M., García-Alfonso, P., Neyns, B., Luppi, G., Cardin, D. B., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01015 · Cited by 728
CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression
Sun, X., Cheng, G., Hao, M., Zheng, J., Zhou, X., Zhang, J., Taichman, R. S., Pienta, K. J., & Wang, J. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9256-x · Cited by 727
WNT/β-catenin pathway activation correlates with immune exclusion across human cancers
Luke, J. J., Bao, R., Sweis, R. F., Spranger, S., & Gajewski, T. F. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1942 · Cited by 722
Self-citationSchietinger, A., Philip, M., Krisnawan, V. E., Chiu, E. Y., Delrow, J. J., Basom, R. S., Lauer, P., Brockstedt, D. G., Knoblaugh, S. E., Hämmerling, G. J., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.07.011 · Cited by 720 · cited 1×
“Antigen encounter by DCs in a non-inflammatory context can, therefore, lead to early and tumour-specific T cell dysfunction 123 .”
Chow, M. T., Ozga, A. J., Servis, R. L., Frederick, D. T., Lo, J. A., Fisher, D. E., Freeman, G. J., Boland, G. M., & Luster, A. D. (2019) · Immunity · doi:10.1016/j.immuni.2019.04.010 · Cited by 716
Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies
Anderson, K. G., Stromnes, I. M., & Greenberg, P. D. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.008 · Cited by 702
Regulation of PD-L1 expression in the tumor microenvironment
Yi, M., Niu, M., Xu, L., Luo, S., & Wu, K. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01027-5 · Cited by 681 · cited 2×
“It is conceivable, however, that sequential targeting of different subclones could be hindered by a failure to fully eliminate the dominant antigen-expressing subclone or by the induction of a highly immunosuppressive TME, including IFNγ-induced upregulation of PDL1 on tumour cells 36 .”
Linnemann, C., van Buuren, M. M., Bies, L., Verdegaal, E. M. E., Schotte, R., Calis, J. J. A., Behjati, S., Velds, A., Hilkmann, H., Atmioui, D. E., et al. (2015) · Nature Medicine · doi:10.1038/nm.3773 · Cited by 679
Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes
Shukla, S. A., Rooney, M. S., Rajasagi, M., Tiao, G., Dixon, P. M., Lawrence, M. S., Stevens, J., Lane, W. J., Dellagatta, J. L., Steelman, S., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3344 · Cited by 675
Dendritic cell subsets in cancer immunity and tumor antigen sensing
Del Prete, A., Salvi, V., Soriani, A., Laffranchi, M., Sozio, F., Bosisio, D., & Sozzani, S. (2023) · Cellular & Molecular Immunology · doi:10.1038/s41423-023-00990-6 · Cited by 644
Liu, Y., Gu, Y., Han, Y., Zhang, Q., Jiang, Z., Zhang, X., Huang, B., Xu, X., Zheng, J., & Cao, X. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.06.021 · Cited by 640
Identification of neutral tumor evolution across cancer types
Williams, M. J., Werner, B., Barnes, C. P., Graham, T. A., & Sottoriva, A. (2016) · Nature Genetics · doi:10.1038/ng.3489 · Cited by 625
KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer
Liao, W., Overman, M. J., Boutin, A. T., Shang, X., Zhao, D., Dey, P., Li, J., Wang, G., Lan, Z., Li, J., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.02.008 · Cited by 617 · cited 1×
“…or reduction can result from altered cancer cell-intrinsic signalling (for example, due to impaired interferon responsiveness 76 , KRAS mutations 77 and MYC amplifications 9 ) or from loss-of-function mutations affecting HLA class I heavy chains 37,68,69 , β2-microglobulin 67,71 or proteins…”
cDC1 prime and are licensed by CD4(+) T cells to induce anti-tumour immunity
Ferris, S. T., Durai, V., Wu, R., Theisen, D. J., Ward, J. P., Bern, M. D., Davidson, J. T., Bagadia, P., Liu, T., Briseño, C. G., et al. (2020) · Nature · doi:10.1038/s41586-020-2611-3 · Cited by 611
Key chemokines direct migration of immune cells in solid tumors
Kohli, K., Pillarisetty, V. G., & Kim, T. S. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-021-00303-x · Cited by 583
Tumeh, P. C., Hellmann, M. D., Hamid, O., Tsai, K. K., Loo, K. L., Gubens, M. A., Rosenblum, M., Harview, C. L., Taube, J. M., Handley, N., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0325 · Cited by 560
Hu, Z., Leet, D. E., Allesøe, R. L., Oliveira, G., Li, S., Luoma, A. M., Liu, J., Forman, J., Huang, T., Iorgulescu, J. B., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-01206-4 · Cited by 538
Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes
Dentro, S. C., Leshchiner, I., Haase, K., Tarabichi, M., Wintersinger, J., Deshwar, A. G., Yu, K., Rubanova, Y., Macintyre, G., Demeulemeester, J., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.009 · Cited by 533
Expression of tumour-specific antigens underlies cancer immunoediting
DuPage, M., Mazumdar, C., Schmidt, L. M., Cheung, A. F., & Jacks, T. (2012) · Nature · doi:10.1038/nature10803 · Cited by 529
Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer
Kitajima, S., Ivanova, E., Guo, S., Yoshida, R., Campisi, M., Sundararaman, S. K., Tange, S., Mitsuishi, Y., Thai, T. C., Masuda, S., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0689 · Cited by 526
Mikucki, M. E., Fisher, D. T., Matsuzaki, J., Skitzki, J. J., Gaulin, N. B., Muhitch, J. B., Ku, A. W., Frelinger, J. G., Odunsi, K., Gajewski, T. F., et al. (2015) · Nature Communications · doi:10.1038/ncomms8458 · Cited by 512
George, S., Miao, D., Demetri, G. D., Adeegbe, D., Rodig, S. J., Shukla, S., Lipschitz, M., Amin-Mansour, A., Raut, C. P., Carter, S. L., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.02.001 · Cited by 483
Casbon, A.-J., Reynaud, D., Park, C., Khuc, E., Gan, D. D., Schepers, K., Passegué, E., & Werb, Z. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424927112 · Cited by 470
Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers
Cleary, A. S., Leonard, T. L., Gestl, S. A., & Gunther, E. J. (2014) · Nature · doi:10.1038/nature13187 · Cited by 465
Lee, K. A., Thomas, A. M., Bolte, L. A., Björk, J. R., de Ruijter, L. K., Armanini, F., Asnicar, F., Blanco-Miguez, A., Board, R., Calbet-Llopart, N., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01695-5 · Cited by 464 · cited 1×
“Its role in modulating T cell function has recently gained attention as data show an association between microbiome quality and responsiveness to ICB 168,169 and chimeric antigen receptor (CAR)-”
Single-cell analysis reveals new evolutionary complexity in uveal melanoma
Durante, M. A., Rodriguez, D. A., Kurtenbach, S., Kuznetsov, J. N., Sanchez, M. I., Decatur, C. L., Snyder, H., Feun, L. G., Livingstone, A. S., & Harbour, J. W. (2020) · Nature Communications · doi:10.1038/s41467-019-14256-1 · Cited by 460
Bloch, O., Crane, C. A., Kaur, R., Safaee, M., Rutkowski, M. J., & Parsa, A. T. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3314 · Cited by 458
Jiménez-Sánchez, A., Memon, D., Pourpe, S., Veeraraghavan, H., Li, Y., Vargas, H. A., Gill, M. B., Park, K. J., Zivanovic, O., Konner, J., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.025 · Cited by 458
Evolution of Metastases in Space and Time under Immune Selection
Angelova, M., Mlecnik, B., Vasaturo, A., Bindea, G., Fredriksen, T., Lafontaine, L., Buttard, B., Morgand, E., Bruni, D., Jouret-Mourin, A., et al. (2018) · Cell · doi:10.1016/j.cell.2018.09.018 · Cited by 457
Endogenous naive CD8+ T cell precursor frequency regulates primary and memory responses to infection
Obar, J. J., Khanna, K. M., & Lefrançois, L. (2008) · Immunity · doi:10.1016/j.immuni.2008.04.010 · Cited by 449
See no evil, hear no evil, do no evil: the lessons of immune privilege
Niederkorn, J. Y. (2006) · Nature Immunology · doi:10.1038/ni1328 · Cited by 447
A vaccine targeting mutant IDH1 in newly diagnosed glioma
Platten, M., Bunse, L., Wick, A., Bunse, T., Le Cornet, L., Harting, I., Sahm, F., Sanghvi, K., Tan, C. L., Poschke, I., et al. (2021) · Nature · doi:10.1038/s41586-021-03363-z · Cited by 432
Mroz, E. A., & Rocco, J. W. (2013) · Oral Oncology · doi:10.1016/j.oraloncology.2012.09.007 · Cited by 417
Interplay of natural killer cells and their receptors with the adaptive immune response
Raulet, D. H. (2004) · Nature Immunology · doi:10.1038/ni1114 · Cited by 413
Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas
Kohanbash, G., Carrera, D. A., Shrivastav, S., Ahn, B. J., Jahan, N., Mazor, T., Chheda, Z. S., Downey, K. M., Watchmaker, P. B., Beppler, C., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90644 · Cited by 410
Lu, Y.-C., Yao, X., Crystal, J. S., Li, Y. F., El-Gamil, M., Gross, C., Davis, L., Dudley, M. E., Yang, J. C., Samuels, Y., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0433 · Cited by 401
Huinen, Z. R., Huijbers, E. J. M., van Beijnum, J. R., Nowak-Sliwinska, P., & Griffioen, A. W. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00496-y · Cited by 395
Immune tolerance: What is unique about the liver
Tiegs, G., & Lohse, A. W. (2010) · Journal of Autoimmunity · doi:10.1016/j.jaut.2009.08.008 · Cited by 394
Grasso, C. S., Tsoi, J., Onyshchenko, M., Abril-Rodriguez, G., Ross-Macdonald, P., Wind-Rotolo, M., Champhekar, A., Medina, E., Torrejon, D. Y., Shin, D. S., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.005 · Cited by 390
UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma
Wolf, Y., Bartok, O., Patkar, S., Eli, G. B., Cohen, S., Litchfield, K., Levy, R., Jiménez-Sánchez, A., Trabish, S., Lee, J. S., et al. (2019) · Cell · doi:10.1016/j.cell.2019.08.032 · Cited by 380
Risom, T., Glass, D. R., Averbukh, I., Liu, C. C., Baranski, A., Kagel, A., McCaffrey, E. F., Greenwald, N. F., Rivero-Gutiérrez, B., Strand, S. H., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.023 · Cited by 372
A Functional Role for Tumor Cell Heterogeneity in a Mouse Model of Small Cell Lung Cancer
Calbo, J., van Montfort, E., Proost, N., van Drunen, E., Beverloo, H. B., Meuwissen, R., & Berns, A. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.021 · Cited by 369
Tumor evolution: Linear, branching, neutral or punctuated?
Davis, A., Gao, R., & Navin, N. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.01.003 · Cited by 352
Epigenetics and Cancer Stem Cells: Unleashing, Hijacking, and Restricting Cellular Plasticity
Wainwright, E. N., & Scaffidi, P. (2017) · Trends in Cancer · doi:10.1016/j.trecan.2017.04.004 · Cited by 342
Cromme, F. V., Airey, J., Heemels, M. T., Ploegh, H. L., Keating, P. J., Stern, P. L., Meijer, C. J., & Walboomers, J. M. (1994) · The Journal of experimental medicine · doi:10.1084/jem.179.1.335 · Cited by 330
The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy
Zingg, D., Arenas-Ramirez, N., Sahin, D., Rosalia, R. A., Antunes, A. T., Haeusel, J., Sommer, L., & Boyman, O. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.07.007 · Cited by 330
Mlecnik, B., Tosolini, M., Charoentong, P., Kirilovsky, A., Bindea, G., Berger, A., Camus, M., Gillard, M., Bruneval, P., Fridman, W., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.10.057 · Cited by 328
Systemic dysfunction and plasticity of the immune macroenvironment in cancer models
Allen, B. M., Hiam, K. J., Burnett, C. E., Venida, A., DeBarge, R., Tenvooren, I., Marquez, D. M., Cho, N. W., Carmi, Y., & Spitzer, M. H. (2020) · Nature Medicine · doi:10.1038/s41591-020-0892-6 · Cited by 328
Ovarian cancer mutational processes drive site-specific immune evasion
Vázquez-García, I., Uhlitz, F., Ceglia, N., Lim, J. L. P., Wu, M., Mohibullah, N., Niyazov, J., Ruiz, A. E. B., Boehm, K. M., Bojilova, V., et al. (2022) · Nature · doi:10.1038/s41586-022-05496-1 · Cited by 324
The Role of Naive T Cell Precursor Frequency and Recruitment in Dictating Immune Response Magnitude
Jenkins, M. K., & Moon, J. J. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102661 · Cited by 309
Heterogeneity of the tumor immune microenvironment and its clinical relevance
Jia, Q., Wang, A., Yuan, Y., Zhu, B., & Long, H. (2022) · Experimental Hematology & Oncology · doi:10.1186/s40164-022-00277-y · Cited by 300
Horst, A. K., Neumann, K., Diehl, L., & Tiegs, G. (2016) · Cellular & Molecular Immunology · doi:10.1038/cmi.2015.112 · Cited by 295 · cited 1×
“For instance, the tolerogenic milieu of the liver, which is characterized by a high abundance of anti-inflammatory cytokines 149 , favours metastatic seeding to this site 138,150 .”
Sugiyama, E., Togashi, Y., Takeuchi, Y., Shinya, S., Tada, Y., Kataoka, K., Tane, K., Sato, E., Ishii, G., Goto, K., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.aav3937 · Cited by 289
Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors
Bonde, A.-K., Tischler, V., Kumar, S., Soltermann, A., & Schwendener, R. A. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-35 · Cited by 283
Breast tumor microenvironment structures are associated with genomic features and clinical outcome
Danenberg, E., Bardwell, H., Zanotelli, V. R. T., Provenzano, E., Chin, S.-F., Rueda, O. M., Green, A., Rakha, E., Aparicio, S., Ellis, I. O., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01041-y · Cited by 274
Epigenetic heterogeneity in cancer
Guo, M., Peng, Y., Gao, A., Du, C., & Herman, J. G. (2019) · Biomarker Research · doi:10.1186/s40364-019-0174-y · Cited by 270
Immunological, paracrine and endocrine aspects of testicular immune privilege
Meinhardt, A., & Hedger, M. P. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.03.022 · Cited by 262
Hammerl, D., Martens, J. W. M., Timmermans, M., Smid, M., Trapman-Jansen, A. M., Foekens, R., Isaeva, O. I., Voorwerk, L., Balcioglu, H. E., Wijers, R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25962-0 · Cited by 262
Pozzi, L.-A. M., Maciaszek, J. W., & Rock, K. L. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.4.2071 · Cited by 259
Stein-Thoeringer, C. K., Saini, N. Y., Zamir, E., Blumenberg, V., Schubert, M.-L., Mor, U., Fante, M. A., Schmidt, S., Hayase, E., Hayase, T., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02234-6 · Cited by 255 · cited 1×
“T cell therapy 170 (reviewed in detail elsewhere 171 ).”
Watson, N. F. S., Ramage, J. M., Madjd, Z., Spendlove, I., Ellis, I. O., Scholefield, J. H., & Durrant, L. G. (2006) · International Journal of Cancer · doi:10.1002/ijc.21303 · Cited by 254
Hwang, I., Kim, J. W., Ylaya, K., Chung, E. J., Kitano, H., Perry, C., Hanaoka, J., Fukuoka, J., Chung, J.-Y., & Hewitt, S. M. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02618-z · Cited by 253
Cancer evolution: Darwin and beyond
Vendramin, R., Litchfield, K., & Swanton, C. (2021) · The EMBO Journal · doi:10.15252/embj.2021108389 · Cited by 252
The evolution of non-small cell lung cancer metastases in TRACERx
Al Bakir, M., Huebner, A., Martínez-Ruiz, C., Grigoriadis, K., Watkins, T. B. K., Pich, O., Moore, D. A., Veeriah, S., Ward, S., Laycock, J., et al. (2023) · Nature · doi:10.1038/s41586-023-05729-x · Cited by 251
Righi, E., Kashiwagi, S., Yuan, J., Santosuosso, M., Leblanc, P., Ingraham, R., Forbes, B., Edelblute, B., Collette, B., Xing, D., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3143 · Cited by 245
CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose
Kurts, C., Sutherland, R. M., Davey, G., Li, M., Lew, A. M., Blanas, E., Carbone, F. R., Miller, J. F. A. P., & Heath, W. R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.22.12703 · Cited by 245
Jiménez-Sánchez, A., Cybulska, P., Mager, K. L., Koplev, S., Cast, O., Couturier, D.-L., Memon, D., Selenica, P., Nikolovski, I., Mazaheri, Y., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0630-5 · Cited by 243
A unique tumor antigen produced by a single amino acid substitution
Monach, P. A., Meredith, S. C., T.Siegel, C., & Schreiber, H. (1995) · Immunity · doi:10.1016/1074-7613(95)90078-0 · Cited by 241
Leukemic stem cells and therapy resistance in acute myeloid leukemia
Stelmach, P., & Trumpp, A. (2023) · Haematologica · doi:10.3324/haematol.2022.280800 · Cited by 241
Circulating hematopoietic stem and progenitor cells are myeloid-biased in cancer patients
Wu, W.-C., Sun, H.-W., Chen, H.-T., Liang, J., Yu, X.-J., Wu, C., Wang, Z., & Zheng, L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320753111 · Cited by 227
Divergent clonal differentiation trajectories of T cell exhaustion
Daniel, B., Yost, K. E., Hsiung, S., Sandor, K., Xia, Y., Qi, Y., Hiam-Galvez, K. J., Black, M., J. Raposo, C., Shi, Q., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01337-5 · Cited by 224
Meyer, M. A., Baer, J. M., Knolhoff, B. L., Nywening, T. M., Panni, R. Z., Su, X., Weilbaecher, K. N., Hawkins, W. G., Ma, C., Fields, R. C., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03600-6 · Cited by 217
Fang, J., Lu, Y., Zheng, J., Jiang, X., Shen, H., Shang, X., Lu, Y., & Fu, P. (2023) · Cell Death & Disease · doi:10.1038/s41419-023-06119-x · Cited by 209
How the TCR balances sensitivity and specificity for the recognition of self and pathogens
Morris, G. P., & Allen, P. M. (2012) · Nature Immunology · doi:10.1038/ni.2190 · Cited by 208
Neoantigen quality predicts immunoediting in survivors of pancreatic cancer
Łuksza, M., Sethna, Z. M., Rojas, L. A., Lihm, J., Bravi, B., Elhanati, Y., Soares, K., Amisaki, M., Dobrin, A., Hoyos, D., et al. (2022) · Nature · doi:10.1038/s41586-022-04735-9 · Cited by 206
Kotturi, M. F., Scott, I., Wolfe, T., Peters, B., Sidney, J., Cheroutre, H., von Herrath, M. G., Buchmeier, M. J., Grey, H., & Sette, A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.3.2124 · Cited by 205
Nie, Y. (2001) · Carcinogenesis · doi:10.1093/carcin/22.10.1615 · Cited by 202
Immune cell compartmentalization for brain surveillance and protection
Croese, T., Castellani, G., & Schwartz, M. (2021) · Nature Immunology · doi:10.1038/s41590-021-00994-2 · Cited by 190
Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy
Puig-Saus, C., Sennino, B., Peng, S., Wang, C. L., Pan, Z., Yuen, B., Purandare, B., An, D., Quach, B. B., Nguyen, D., et al. (2023) · Nature · doi:10.1038/s41586-023-05787-1 · Cited by 190
Donadon, M., Torzilli, G., Cortese, N., Soldani, C., Tommaso, L. D., Franceschini, B., Carriero, R., Barbagallo, M., Rigamonti, A., Anselmo, A., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20191847 · Cited by 187
Sharma, S. K., Chintala, N. K., Vadrevu, S. K., Patel, J., Karbowniczek, M., & Markiewski, M. M. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1403215 · Cited by 184
Huang, H., Langenkamp, E., Georganaki, M., Loskog, A., Fuchs, P. F., Dieterich, L. C., Kreuger, J., & Dimberg, A. (2015) · The FASEB Journal · doi:10.1096/fj.14-250985 · Cited by 182
McDonald, K.-A., Kawaguchi, T., Qi, Q., Peng, X., Asaoka, M., Young, J., Opyrchal, M., Yan, L., Patnaik, S., Otsuji, E., et al. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07338-3 · Cited by 180
Type 1 conventional dendritic cells are systemically dysregulated early in pancreatic carcinogenesis
Lin, J. H., Huffman, A. P., Wattenberg, M. M., Walter, D. M., Carpenter, E. L., Feldser, D. M., Beatty, G. L., Furth, E. E., & Vonderheide, R. H. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20190673 · Cited by 178
Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer
Karn, T., Jiang, T., Hatzis, C., Sänger, N., El‐Balat, A., Rody, A., Holtrich, U., Becker, S., Bianchini, G., & Pusztai, L. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.2140 · Cited by 177
Rappaport, A., Kyi, C., Lane, M., Hart, M. G., Johnson, M. L., Henick, B. S., Liao, C., Mahipal, A., Shergill, A. P., Spira, A. I., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02851-9 · Cited by 176
Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer
Westcott, P. M. K., Sacks, N. J., Schenkel, J. M., Ely, Z. A., Smith, O., Hauck, H., Jaeger, A. M., Zhang, D., Backlund, C. M., Beytagh, M. C., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00247-z · Cited by 175
Zagorulya, M., Yim, L., Morgan, D. M., Edwards, A. W., Torres-Mejia, E., Momin, N., McCreery, C. V., Zamora, I., Horton, B. L., Fox, J. G., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.01.010 · Cited by 175
Self-citationConnecting blood and intratumoral Treg cell activity in predicting future relapse in breast cancer
Wang, L., Simons, D. L., Lu, X., Tu, T. Y., Solomon, S., Wang, R., Rosario, A., Avalos, C., Schmolze, D., Yim, J., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0429-7 · Cited by 174
Manuel, M., Trédan, O., Bachelot, T., Clapisson, G., Courtier, A., Parmentier, G., Rabeony, T., Grivès, A., Perez, S., Mouret, J.-F., et al. (2012) · OncoImmunology · doi:10.4161/onci.19545 · Cited by 172
Chheda, Z. S., Sharma, R. K., Jala, V. R., Luster, A. D., & Haribabu, B. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1502376 · Cited by 170
Dominguez, C., McCampbell, K. K., David, J. M., & Palena, C. (2017) · JCI Insight · doi:10.1172/jci.insight.94296 · Cited by 170
Wang, W., Yuan, X.-L., Chen, H., Xie, G.-H., Ma, Y., Zheng, Y., Zhou, Y., & Shen, L.-S. (2015) · Oncotarget · doi:10.18632/oncotarget.5588 · Cited by 169
Yan, J., Parekh, V. V., Mendez-Fernandez, Y., Olivares-Villagómez, D., Dragovic, S., Hill, T., Roopenian, D. C., Joyce, S., & Van Kaer, L. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052271 · Cited by 167
Antigen Dominance Hierarchies Shape TCF1+ Progenitor CD8 T Cell Phenotypes in Tumors
Burger, M. L., Cruz, A. M., Crossland, G. E., Gaglia, G., Ritch, C. C., Blatt, S. E., Bhutkar, A. J., Canner, D. A., Kienka, T., Tavana, S. Z., et al. (2021) · Cell · doi:10.1016/j.cell.2021.08.020 · Cited by 167
Schuijs, M. J., Png, S., Richard, A. C., Tsyben, A., Hamm, G., Stockis, J., Garcia, C., Pinaud, S., Nicholls, A., Ros, X. R., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0745-y · Cited by 165
Mismatch repair deficiency is not sufficient to elicit tumor immunogenicity
Westcott, P. M. K., Muyas, F., Hauck, H., Smith, O. C., Sacks, N. J., Ely, Z. A., Jaeger, A. M., Rideout, W. M., Zhang, D., Bhutkar, A., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01499-4 · Cited by 165
Oncogenic KRAS signalling promotes the Wnt/β-catenin pathway through LRP6 in colorectal cancer
Lemieux, E., Cagnol, S., Beaudry, K., Carrier, J., & Rivard, N. (2015) · Oncogene · doi:10.1038/onc.2014.416 · Cited by 164
van Elsas, M. J., Middelburg, J., Labrie, C., Roelands, J., Schaap, G., Sluijter, M., Tonea, R., Ovcinnikovs, V., Lloyd, K., Schuurman, J., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.04.011 · Cited by 163
Cancer immune escape: the role of antigen presentation machinery
Kallingal, A., Olszewski, M., Maciejewska, N., Brankiewicz, W., & Bagiński, M. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04737-8 · Cited by 160
Subclonal cooperation drives metastasis by modulating local and systemic immune microenvironments
Janiszewska, M., Tabassum, D. P., Castaño, Z., Cristea, S., Yamamoto, K. N., Kingston, N. L., Murphy, K. C., Shu, S., Harper, N. W., Del Alcazar, C. G., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0346-x · Cited by 159
Chen, G., Yang, X., Ko, A., Sun, X., Gao, M., Zhang, Y., Shi, A., Mariuzza, R. A., & Weng, N. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.03.072 · Cited by 157
Nguyen, P. H. D., Ma, S., Phua, C. Z. J., Kaya, N. A., Lai, H. L. H., Lim, C. J., Lim, J. Q., Wasser, M., Lai, L., Tam, W. L., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20171-7 · Cited by 156
Mitchison, N. A., & O'Malley, C. (1987) · European Journal of Immunology · doi:10.1002/eji.1830171109 · Cited by 154
PyClone-VI: scalable inference of clonal population structures using whole genome data
Gillis, S., & Roth, A. J. L. (2020) · BMC Bioinformatics · doi:10.1186/s12859-020-03919-2 · Cited by 153
Huber, R., Meier-Schiesser, B., Otsuka, A., Fenini, G., Satoh, T. K., Gehrke, S., Widmer, D., Levesque, M. P., Mangana, J., Kerl, K., et al. (2016) · Scientific Reports · doi:10.1038/srep29914 · Cited by 151
Bell, C. R., Pelly, V. S., Moeini, A., Chiang, S., Flanagan, E., Bromley, C. P., Clark, C. I., Earnshaw, C. H., Koufaki, M. A., Bonavita, E., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29606-9 · Cited by 149
Yoon, H., Tang, C., Banerjee, S., Delgado, A. L., Yebra, M., Davis, J. E., & Sicklick, J. K. (2021) · Oncogenesis · doi:10.1038/s41389-021-00302-5 · Cited by 140
Lin, A., & Yan, W. (2015) · Molecular Medicine · doi:10.2119/molmed.2015.00083 · Cited by 137
Liu, Y., Yang, Q., Yang, J., Cao, R., Liang, J., Liu, Y., Zeng, Y., Chen, S., Xia, X., Zhang, K., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32145 · Cited by 134
Selection for β2-microglobulin mutation in mismatch repair-defective colorectal carcinomas
Bicknell, D., Kaklamanis, L., Hampson, R., Bodmer, W. F., & Karran, P. (1996) · Current Biology · doi:10.1016/s0960-9822(02)70795-1 · Cited by 132
Bilen, M. A., Shabto, J. M., Martini, D. J., Liu, Y., Lewis, C. M., Collins, H., Akce, M., Kissick, H. T., Carthon, B. C., Shaib, W. L., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-6073-7 · Cited by 132
Nguyen, T. H. O., Rowntree, L. C., Petersen, J., Chua, B. Y. L., Hensen, L., Kedzierski, Ł., van de Sandt, C. E., Chaurasia, P., Tan, H., Habel, J. R., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.04.009 · Cited by 132
Horton, B. L., Morgan, D. M., Momin, N., Zagorulya, M., Torres-Mejia, E., Bhandarkar, V., Wittrup, K. D., Love, J. C., & Spranger, S. (2021) · Science Immunology · doi:10.1126/sciimmunol.abi8800 · Cited by 131
Self-citationRejection of immunogenic tumor clones is limited by clonal fraction
Gejman, R. S., Chang, A. Y., Jones, H. F., DiKun, K. M., Hakimi, A. A., Schietinger, A., & Scheinberg, D. A. (2018) · eLife · doi:10.7554/elife.41090 · Cited by 129
Vianello, F., Papeta, N., Chen, T., Kraft, P., White, N., Hart, W. K., Kircher, M. F., Swart, E., Rhee, S. S., Palù, G., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.5.2902 · Cited by 126
Yang, S. Y. C., Lien, S. C., Wang, B. X., Clouthier, D., Hanna, Y., Cirlan, I., Zhu, K., Bruce, J. P., Ghamrasni, S. E., Iafolla, M. A. J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25432-7 · Cited by 125
CAR-T cells and BiTEs in solid tumors: challenges and perspectives
Edeline, J., Houot, R., Marabelle, A., & Alcantara, M. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01067-5 · Cited by 123
Bayesian inference of negative and positive selection in human cancers
Weghorn, D., & Sunyaev, S. R. (2017) · Nature Genetics · doi:10.1038/ng.3987 · Cited by 122
The immune system profoundly restricts intratumor genetic heterogeneity
Milo, I., Bedora-Faure, M., Garcia, Z., Thibaut, R., Perié, L., Shakhar, G., Deriano, L., & Bousso, P. (2018) · Science Immunology · doi:10.1126/sciimmunol.aat1435 · Cited by 116
Intratumor heterogeneity defines treatment‐resistant HER 2+ breast tumors
Rye, I. H., Trinh, A., Sætersdal, A. B., Nebdal, D. J. H., Lingjærde, O. C., Almendro, V., Polyák, K., Børresen‐Dale, A., Helland, Å., Markowetz, F. M., et al. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12375 · Cited by 113
Song, I., Gil, A., Mishra, R., Ghersi, D., Selin, L. K., & Stern, L. J. (2017) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3383 · Cited by 112
Breast cancers, mammary stem cells, and cancer stem cells, characteristics, and hypotheses
Taurin, S., & Alkhalifa, H. (2020) · Neoplasia · doi:10.1016/j.neo.2020.09.009 · Cited by 112
PTEN loss correlates with T cell exclusion across human cancers
Lin, Z., Huang, L., Li, S. L., Gu, J., Cui, X., & Zhou, Y. (2021) · BMC Cancer · doi:10.1186/s12885-021-08114-x · Cited by 106
Tumor-associated macrophage polarization in the inflammatory tumor microenvironment
Zou, Z., Lin, H., Li, M., & Lin, B. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1103149 · Cited by 100
Tjomsland, V., Niklasson, L., Sandström, P., Borch, K., Druid, H., Bratthäll, C., Messmer, D., Larsson, M., & Spångéus, A. (2011) · Clinical and Developmental Immunology · doi:10.1155/2011/212810 · Cited by 99
Kinetics of Expansion of Epitope-Specific T Cell Responses during Primary HIV-1 Infection
Turnbull, E. L., Wong, M., Wang, S., Wei, X., Jones, N., Conrod, K. E., Aldam, D., Turner, J., Pellegrino, P., Keele, B. F., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803658 · Cited by 99
Metadata
- Authors
- Roerden, M., & Spranger, S.
- Venue
- Nature Reviews Immunology
- Published
- 2025-01-02
- Volume
- 25
- Issue
- 5
- Pages
- 353-369
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W4405983094
- Cited by
- 265
- References
- 249
- FWCI
- 51.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.